Lowering apolipoprotein CIII delays onset of type 1 diabetes

Serum levels of apolipoprotein CIII (apoCIII) are increased in type 1 diabetic patients, and when β cells are exposed to these diabetic sera, apoptosis occurs, an effect abolished by an antibody against apoCIII. We have investigated the BB rat, an animal model that develops a human-like type 1 diabetes, and found that apoCIII was also increased in sera from prediabetic rats. This increase in apoCIII promoted β-cell death. The endogenous levels of apoCIII were reduced by treating prediabetic animals with an antisense against this apolipoprotein, resulting in a significantly delayed onset of diabetes. ApoCIII thus serves as a diabetogenic factor, and intervention with this apolipoprotein in the prediabetic state can arrest disease progression. These findings suggest apoCIII as a target for the treatment of type 1 diabetes.

Refai, EssamKarolinska Institutet (författare)
Höög, AndersKarolinska Institutet (författare)
Crooke, Rosanne M (författare)
Graham, Mark (författare)
Olivecrona, GunillaUmeå universitet,Fysiologisk kemi(Swepub:umu)guol0002 (författare)
Berggren, Per-OlofKarolinska Institutet (författare)
Juntti-Berggren, LisaKarolinska Institutet (författare)
Karolinska InstitutetFysiologisk kemi (creator_code:org_t)

Ingår i:Proceedings of the National Academy of Sciences of the United States of America: National Academy of Sciences108:26, s. 10685-106890027-84241091-6490

Av författaren/redakt...: Holmberg, Rebeck ...; Refai, Essam; Höög, Anders; Crooke, Rosanne ...; Graham, Mark; Olivecrona, Guni ...; visa fler...; Berggren, Per-Ol ...; Juntti-Berggren, ...; visa färre...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.